US Health Chief: Insufficient Data Connecting Tylenol to Autism Risks

U.S. Health Secretary Robert F. Kennedy Jr. recently spoke about the use of Tylenol (acetaminophen) during pregnancy. He emphasized that while there’s no solid evidence linking Tylenol to autism, caution is essential. His comments followed a lawsuit from Texas against Kenvue, the drug’s maker.

Kennedy stated that current research suggests a possible connection between Tylenol and developmental issues in children. He referenced various animal studies and human observations pointing to the need for careful use. Many health experts echo this sentiment. Dr. Ayesha Thomas, a pediatrician, notes, “While we need more research, it’s wise to consult a doctor before taking any medication during pregnancy.”

In September, former President Trump advised pregnant women to avoid Tylenol, although he didn’t provide any scientific backing. This statement caused a stir, affecting Kenvue’s stock prices and drawing criticism from medical professionals.

Kenvue has consistently defended Tylenol, claiming it is safe when taken as directed. The company argues that fears surrounding autism could lead to dangerous health outcomes for mothers, as untreated pain or fever during pregnancy can pose risks. Kenvue has even reached out to the FDA, requesting that no warnings about autism accompany Tylenol’s labeling.

In light of these discussions, it’s worth noting that a study published in 2022 in the journal “Nature Reviews” highlighted a significant rise in acetaminophen use during pregnancy, suggesting that awareness and guidelines are urgently needed.

As debate continues, many users on social media express their concerns about medication safety. Some share personal stories, while others call for clearer guidance from health officials.

The conversation surrounding Tylenol reflects broader concerns about medication use during pregnancy. Health authorities are urged to provide clear, evidence-based recommendations to ensure both maternal and child health remain a priority.



Source link

NRLPA:OPROD,RSBI:REGULATORY-OVERSIGHT,CMPNY,GEN,GENHLT,HCPOL,HEA,HECA,HSEHLD,NCYC,PHAR,PHAR1,PHMR,POL,PSNPR,PSNPR1,PUBL,REGS,WASH,AMERS,US,NAMER,RHPI:REGULATORY,RHPI:PUBLIC-HEALTH,CHLD,DLI,MEDREG,PEDMED,SOCI,WOMHEA,DEST:OUSHEM,HOT,POTUS,TOPIC:PHARMA-HEALTHCARE-CONSUMER-HEALTH,TOPIC:PHARMA-HEALTHCARE-POLICY-REGULATION,STX,DEST:OUSDNM,DEST:OUSTPM,DEST:OCATPM,PACKAGE:US-TOP-NEWS,TOPNWS,TOPCMB,NRLPA:OHLT,LEGAL,REUTERS-LEGAL,DEST:LITA,DEST:OHLT,DEST:OPROD